Evidence map›Paper›PMID 25495906›Full record

ArticlePrion2014

Pretreatment of chemically-synthesized Aβ42 affects its biological activity in yeast.

Afsaneh Porzoor, Joanne M Caine, Ian G Macreadie

Open access · bronzeAbstract read
In one paragraph

Article in Prion, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Alzheimer's Disease: Significant Benefit from the Yeast-Based Models.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Amyloid Beta Peptide Is Released during Thrombosis in the Skin.International journal of molecular sciences · 2018
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Afsaneh Porzoora School of Applied Sciences; Biosciences ; RMIT University ; Bundoora , Victoria , Australia.
Joanne M Caine
Ian G Macreadie
Commonwealth Scientific and Industrial Research Organisation · AUMIT University · MKRMIT University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tendency of amyloid β (Aβ42) peptide to misfold and aggregate into insoluble amyloid fibrils in Alzheimer's disease (AD) has been well documented. Accumulation of Aβ42 fibrils has been correlated with abnormal apoptosis and unscheduled cell division which can also trigger the death of neuronal cells, while oligomers can also exhibit similar activities. While investigations using chemically-synthesized Aβ42 peptide have become common practice, there appear to be differences in outcomes from different preparations. In order to resolve this inconsistency, we report 2 separate methods of preparing chemically-synthesized Aβ42 and we examined their effects in yeast. Hexafluoroisopropanol pretreatment caused toxicity while, ammonium hydroxide treated Aβ42 induced cell proliferation in both C. glabrata and S. cerevisiae. The hexafluoroisopropanol prepared Aβ42 had greater tendency to form amyloid on yeast cells as determined by thioflavin T staining followed by flow cytometry and microscopy. Both quiescent and non-quiescent cells were analyzed by these methods of peptide preparation. Non-quiescent cells were susceptible to the toxicity of Aβ42 compared with quiescent cells (p < 0.005). These data explain the discrepancy in the previous publications about the effects of chemically-synthesized Aβ42 on yeast cells. The effect of Aβ42 on yeast cells was independent of the size of the peptide aggregates. However, the Aβ42 pretreatment determined whether the molecular conformation of peptide resulted in proliferation or toxicity in yeast based assays.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesApoptosisBenzothiazolesCandida glabrataFlow CytometryHydrocarbons, FluorinatedMicroscopy, ConfocalMicroscopy, Electron, TransmissionNeuronsPeptide FragmentsPeptidesPropanolsProtein BindingProtein ConformationSaccharomyces cerevisiaeAmyloid beta-Peptidesamyloid beta-protein (1-42)BenzothiazoleshexafluoroisopropanolHydrocarbons, FluorinatedPeptide FragmentsPeptidesPropanolsThiazolesthioflavin TAlzheimer's diseaseCandida glabratapeptide conformationquiescent cellsSaccharomyces cerevisiaesynthetic Aβ42

Identifiers

PMID25495906
PMCPMC4601261
OpenAlexW2056423919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.